General MedicationsPERIODONTALStandard
ORAQIX
LIDOCAINE; PRILOCAINE
Standard Dose
2.5%;2.5%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ORAQIX is listed in Drugs@FDA under application 021451 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LIDOCAINE; PRILOCAINE Form and strength GEL;PERIODONTAL - 2.5%;2.5% Sponsor DENTSPLY PHARM Submission history Latest submission status date: 2022-03-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview ORAQIX is listed in Drugs@FDA under application 021451 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LIDOCAINE; PRILOCAINE Form and strength GEL;PERIODONTAL - 2.5%;2.5% Sponsor DENTSPLY PHARM Submission history Latest submission status date: 2022-03-02 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.